These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22655211)

  • 1. Targeting the ACE2 and Apelin Pathways Are Novel Therapies for Heart Failure: Opportunities and Challenges.
    Kazemi-Bajestani SM; Patel VB; Wang W; Oudit GY
    Cardiol Res Pract; 2012; 2012():823193. PubMed ID: 22655211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications.
    Chatterjee P; Gheblawi M; Wang K; Vu J; Kondaiah P; Oudit GY
    Clin Sci (Lond); 2020 Sep; 134(17):2319-2336. PubMed ID: 32901821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling.
    Sato T; Kadowaki A; Suzuki T; Ito H; Watanabe H; Imai Y; Kuba K
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30634441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apelin is a positive regulator of ACE2 in failing hearts.
    Sato T; Suzuki T; Watanabe H; Kadowaki A; Fukamizu A; Liu PP; Kimura A; Ito H; Penninger JM; Imai Y; Kuba K
    J Clin Invest; 2013 Dec; 123(12):5203-11. PubMed ID: 24177423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy.
    Oudit GY; Penninger JM
    Curr Heart Fail Rep; 2011 Sep; 8(3):176-83. PubMed ID: 21611889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ACE2/Apelin Signaling, MicroRNAs, and Hypertension.
    Chen LJ; Xu R; Yu HM; Chang Q; Zhong JC
    Int J Hypertens; 2015; 2015():896861. PubMed ID: 25815211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS.
    Patel VB; Clarke N; Wang Z; Fan D; Parajuli N; Basu R; Putko B; Kassiri Z; Turner AJ; Oudit GY
    J Mol Cell Cardiol; 2014 Jan; 66():167-76. PubMed ID: 24332999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of ACE2 in diastolic and systolic heart failure.
    Wang W; Bodiga S; Das SK; Lo J; Patel V; Oudit GY
    Heart Fail Rev; 2012 Sep; 17(4-5):683-91. PubMed ID: 21638102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System.
    Wang W; McKinnie SM; Farhan M; Paul M; McDonald T; McLean B; Llorens-Cortes C; Hazra S; Murray AG; Vederas JC; Oudit GY
    Hypertension; 2016 Aug; 68(2):365-77. PubMed ID: 27217402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apelin and ACE2 in cardiovascular disease.
    Kalea AZ; Batlle D
    Curr Opin Investig Drugs; 2010 Mar; 11(3):273-82. PubMed ID: 20178040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of ACE2 in cardiovascular physiology.
    Oudit GY; Crackower MA; Backx PH; Penninger JM
    Trends Cardiovasc Med; 2003 Apr; 13(3):93-101. PubMed ID: 12691672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs.
    Wang W; Shen M; Fischer C; Basu R; Hazra S; Couvineau P; Paul M; Wang F; Toth S; Mix DS; Poglitsch M; Gerard NP; Bouvier M; Vederas JC; Penninger JM; Kassiri Z; Oudit GY
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):13006-13015. PubMed ID: 31189595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.
    Mendoza-Torres E; Oyarzún A; Mondaca-Ruff D; Azocar A; Castro PF; Jalil JE; Chiong M; Lavandero S; Ocaranza MP
    Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):217-37. PubMed ID: 26275770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure.
    Patel VB; Putko B; Wang Z; Zhong JC; Oudit GY
    Drug Discov Today Ther Strateg; 2012; 9(4):e141-e148. PubMed ID: 32362932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases.
    Kuba K; Imai Y; Penninger JM
    Circ J; 2013; 77(2):301-8. PubMed ID: 23328447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases.
    Parajuli N; Ramprasath T; Patel VB; Wang W; Putko B; Mori J; Oudit GY
    Can J Physiol Pharmacol; 2014 Jul; 92(7):558-65. PubMed ID: 24861775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The functional role of endogenous APJ agonists; Apelin and Elabela/Toddler in cardiovascular diseases].
    Sato T; Kuba K
    Nihon Yakurigaku Zasshi; 2019; 153(4):172-178. PubMed ID: 30971657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Jacques Benoit lecture: the neuroendocrine view of the angiotensin and apelin systems.
    Llorens-Cortes C; Kordon C
    J Neuroendocrinol; 2008 Mar; 20(3):279-89. PubMed ID: 18194430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE2 of the heart: From angiotensin I to angiotensin (1-7).
    Keidar S; Kaplan M; Gamliel-Lazarovich A
    Cardiovasc Res; 2007 Feb; 73(3):463-9. PubMed ID: 17049503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling.
    Patel VB; Zhong JC; Fan D; Basu R; Morton JS; Parajuli N; McMurtry MS; Davidge ST; Kassiri Z; Oudit GY
    Hypertension; 2014 Jul; 64(1):157-64. PubMed ID: 24799609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.